ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1424	National Cancer Institute	Html	en	Liver (Hepatocellular) Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for liver (hepatocellular) cancer.	positive predictive value 0.503935 Needle aspiration cytology 0.492344 10-year survival rates 0.485559 hepatitis B virus 0.608203 hepatitis G infection 0.516552 control group 0.576587 6-monthly AFP assays 0.575205 North America 0.429041 nonalcoholic steatohepatitis 0.42282 AFP screening 0.526835 usual-care group 0.429439 ethnic groups 0.421496 test result 0.419937 HCC 0.942449 screening group 0.63461 Age-standardized incidence rates 0.541219 hepatitis B infection 0.498394 glycogen storage disease 0.517803 porphyria cutanea tarda 0.523911 new cases 0.427232 patients experience pain 0.502381 Serum AFP 0.49956 fetal-specific glycoprotein antigen 0.51455 United States 0.614175	screening tests 0.450593 retrospective case-control study 0.516703 mortality rate ratio 0.509505 certain Aspergillus species 0.510442 widely used tumor 0.501438 cryptogenic cirrhosis 0.452869 earlier diagnosis 0.555097 right upper quadrant 0.485875 common cancer 0.432709 surface antigen–positive carriers 0.524371 diagnosis study designs. 0.509206 Chinese Americans 0.422068 high incidence 0.419907 distinct male preponderance 0.54002 risk factor 0.421115 HCC mortality 0.712636 mortality rate 0.512472 randomized controlled trial 0.492498 alcoholic cirrhosis 0.45216 chronic hepatitis 0.816099 germ cell tumors 0.509004 liver biopsy 0.576034 annual risk 0.42449 liver cancer 0.48682	CLICK HERE
1591	National Cancer Institute	Html	en	Malignant Mesothelioma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of malignant mesothelioma	treatment 0.551287 cancer treatment 0.340662 Malignant Mesothelioma Treatment 0.334116 new cancer treatments 0.298226 abdomen 0.342929 mesothelioma cells 0.302239 NCI-supported cancer 0.30062 cancer cells 0.449527 tissue 0.339682 cancer spreads 0.292278 body 0.347394 type 0.303371 Cancer Information Service 0.298735 PDQ cancer information 0.3972 specific cancer cells 0.306143 lung cancer 0.291541 clinical trial search 0.340298 treatment clinical trials 0.336321 recurrent malignant mesothelioma 0.311655 National Cancer Institute 0.362679 clinical trials 0.762248 Hyperthermic intraperitoneal chemotherapy 0.313279 cancer information summary 0.35973	clinical trial 0.628796 Chest x-ray 0.298921 new treatment 0.392026 chest 0.633578 External radiation therapy 0.296642 malignant mesothelioma 0.93518 malignant mesothelioma spreads 0.321364 patients 0.313483 chest wall 0.457714 treatment clinical trial 0.30192 lung 0.332709 malignant tumor cells 0.339702 NCI PDQ cancer 0.309818 cancer clinical trials 0.370425 palliative therapy 0.314097 chest cavity 0.469318 radiation therapy 0.456968 lining 0.349463 Treatment Editorial Board 0.300565 cancer information summaries 0.296312 comprehensive cancer information 0.296561 cancer 0.910743 standard treatment 0.300992	CLICK HERE
2074	National Cancer Institute	Html	es	Lunares comunes, nevos displásicos y el riesgo de melanoma	Hoja informativa que trata de los lunares y de cómo algunos de ellos pueden relacionarse con el melanoma, el cual es el tipo más grave de cáncer de piel. La hoja informativa incluye fotos de las diferencias entre los lunares y el cáncer y habla de los factores de riesgo para el melanoma.	cutaneous melanoma 0.625563 American Medical Association 0.446245 American Academy 0.427461 Titus-Ernstoff L 0.428273 Farber MJ 0.430084 Retrieved July 0.486153 Cancer Statistics Review 0.452828 melanoma diagnosis 0.625391 raros casos 0.429111 SEER Web site 0.451878 Halpern A 0.427294 American Cancer Society 0.542367 Noone AM 0.428963 Holly EA 0.427203 Warycha MA 0.428668 National Cancer Institute 0.451063 Does Melanoma Look 0.709416 color café 0.453426 quemaduras solares 0.441604 estadounidenses —más 0.43587 atypical moles 0.48786 antecedentes familiares 0.432287 más anchos 0.493483	Family Physician 0.42998 página what does 0.683972 médicos familiares 0.43414 lámparas solares 0.871559 central risk factor 0.448185 patient with 0.429841 years beyond 0.429706 Rigel DS 0.428483 Estados Unidos 0.428522 Krapcho M 0.428389 PubMed Abstract 0.979256 Cyr PR 0.430249 única forma 0.527641 piel al sol 0.463391 Mole Look Like 0.64852 early melanoma detection 0.640669 página luz solar del nci 0.453944 Acta Dermato Venereologica 0.450034 Goodson AG 0.428558 Perry AE 0.427784 Cancer Journal 0.432434 Look Like 0.678163	CLICK HERE
2081	National Cancer Institute	Html	en	Anal Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing anal cancer and about research aimed at the prevention of this disease.	cancer treatment 0.464555 cancer prevention trials 0.498621 vulvar cancer 0.503416 prevention clinical trials 0.493993 protective factors 0.507902 PDQ cancer information 0.625044 following PDQ summary 0.502565 vaginal cancer 0.486585 Clinical Trials section 0.461828 anal canal 0.533777 clinical trials 0.598731 cancer information summary 0.549513 anal cancer prevention 0.663166 breast cancer prevention 0.484596 PDQ summaries 0.467118 cancer patients 0.464335 latest published information 0.460931 cancer risk factor 0.518562 cervical cancer 0.48633 NCI’s PDQ 0.468536 NCI PDQ cancer 0.523892 human papillomavirus 0.494748 new cases 0.483309 main risk factor 0.469293	HPV infections 0.457755 anal HPV infection 0.631746 PDQ Screening 0.46183 cancer risk factors 0.515329 cancer protective factor 0.50012 strong risk factor 0.467497 Cancer Information Service 0.49085 Prevention Editorial Board 0.496384 treatment clinical trials 0.462135 National Cancer Institute 0.554602 anal warts 0.526199 PDQ documents 0.462803 cancer doctors 0.458824 higher risk 0.480616 new treatment 0.461051 anal adenocarcinoma 0.533821 Cancer Care page 0.482785 PDQ database 0.465761 anal cancer 0.96756 PDQ summary 0.51849 anal opening 0.549229 risk factors 0.575476 cancer information summaries 0.495754 comprehensive cancer information 0.496369	CLICK HERE
3417	National Cancer Institute	Html	en	Program History: The Transition from Cooperative Groups to Network Groups	Guided by recommendations in a 2010 Institute of Medicine (IOM) report, the design and implementation of the NCTN incorporated feedback from Cooperative Group investigators, NCI Comprehensive Cancer Center directors, several NCI working groups, leading cancer researchers, industry representatives, and patient advocates.	Cooperative Group investigators 0.723795 decentralized groups 0.553186 Group trials 0.587291 NCI Comprehensive Cancer 0.791421 office operations 0.544686 positive step 0.532998 exciting changes 0.530762 clinical trials 0.762507 individual groups 0.561822 precision cancer medicine 0.628035 NCI working groups 0.821534 prior clinical trials 0.644576 Network Operations 0.599362 —a working group 0.689466 main NCTN page 0.622822 Central Institutional Review 0.642526 industry representatives 0.538064 management tool 0.531744 new systemic treatments 0.630155 fewer centers 0.542085 scientific support services 0.625026 single electronic data 0.644995 best scientific ideas 0.636189 NCTN group 0.548689 Cooperative Groups 0.65687	Data Management Centers 0.621989 Cancer Trials Support 0.688901 current Network Groups 0.658899 data management 0.644423 Cooperative Group Program 0.930818 single ethics 0.537226 U.S. groups 0.548194 additional changes 0.541529 oncologic science 0.530663 IOM report 0.822082 patient advocates 0.539798 Clinical Trials Network 0.651945 adult groups 0.550791 Center directors 0.548399 expert committees 0.631765 multicenter trials 0.566499 cancer researchers 0.557077 scientific opportunities 0.545896 Efficiency Working Group 0.675675 activating clinical trials 0.676936 patient registration tasks 0.642657 earlier NCI 0.63686 Cooperative Group Operations 0.704636 different groups 0.567071	CLICK HERE
3418	National Cancer Institute	Html	es	Infección por VIH y el riesgo de cáncer	Hoja informativa que describe el mayor riesgo de ciertos tipos de cánceres que presentan las personas con infección por VIH.	American Medical Association 0.305472 Massad LS 0.304504 persons living with 0.309758 Clinical Pathology 0.305446 Engels EA 0.324229 Instituto Nacional 0.322224 immunodeficiency virus 0.308559 hiv-infected populations 0.314373 risk factors 0.305288 living with hiv 0.312034 Park LS 0.311156 Nelson M 0.309125 PubMed Abstract 0.984124 Shiels MS 0.343807 World Journal 0.305246 ¿Por qué las personas 0.315076 linfoma no de hodgkin 0.312884 clinical effectiveness 0.305165 Clinical Oncology 0.316457 Crothers K 0.311791 Hernández-Ramírez RU 0.312425 among hiv-infected 0.323339 HIV-infected individuals with 0.313039 United States 0.321371 alto riesgo 0.323822	Hepatocellular carcinoma 0.310863 Current Infectious Disease 0.307352 Cáncer Anal 0.326643 Current Opinion 0.313646 among hiv-infected patients 0.309712 non-aids-defining malignancies 0.312665 Abrams DI 0.311942 Silverberg MJ 0.372078 Lancet HIV 0.307746 viral hepatitis 0.30657 alta malignidad 0.305701 Dubrow R 0.325909 mortality among hiv-infected 0.321932 linfoma no Hodgkin 0.307666 HIV-infected individuals 0.327913 with hiv 0.319383 cuello uterino 0.369826 living with 0.313701 trends among hiv-infected 0.308907 persons with hiv 0.312445 Powles T 0.310265 New England Journal 0.320004 Acquired Immune Deficiency 0.306759 Coghill AE 0.311775	CLICK HERE
3442	National Cancer Institute	Html	es	Prevención del cáncer de cavidad oral y orofaringe (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de labio, cavidad oral y orofaringe, y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	accessed july 0.289947 La Vecchia C 0.313315 IARC Monogr Eval 0.379143 Human Services 0.286547 Cancer Statistics Review 0.332297 bivalent hpv vaccination 0.278094 Cancer Institute Manual 0.271785 American Cancer Society 0.641714 Health Promotion 0.256136 case-control study 0.283986 after bivalent hpv 0.277346 efecto multiplicador 0.286431 Instituto Nacional 0.252616 Cancer Prev 0.267564 IARC Working Group 0.372919 years after bivalent 0.27259 Estados Unidos 0.299649 Cancer Incidence 0.261063 Natl Cancer Inst 0.275659 alcohol drinking 0.261621 Saraiya M 0.244224 human papillomavirus 0.860712 SEER Cancer Statistics 0.335541 Emerg Infect Dis 0.273541 Hashibe M 0.245439	Public Health 0.254115 Oral Health Team 0.299673 Health Consequences 0.257211 Eval Carcinog Risks 0.372932 Cancer Facts 0.324993 Carcinogenic Risks 0.298434 alcohol consumption 0.289008 Alcohol Res Health 0.244887 Oral Oncol 0.440457 tobacco smoking 0.273955 National Cancer Institute 0.993247 Monogr Eval Carcinog 0.360728 accessed april 0.342134 Kreimer AR 0.333079 Betel quid chewing 0.406373 Clin Oncol 0.248367 Clin North Am 0.271933 areca-nut derived nitrosamines 0.274755 Chronic Disease Prevention 0.274687 Carcinog Risks Hum 0.370704 meta-analysis with implications 0.275074 oral cavity 0.505696 riesgo aumenta 0.266836 Johansson M 0.245017	CLICK HERE
3518	National Cancer Institute	Html	en	Use of Placebos	Information about placebos and their role in cancer clinical trials.	new treatment 0.545554 study 0.364583 patients 0.362034 medicine 0.367624 way 0.414648 treatment group 0.529513 to. 0.361225	doctors 0.371883 treatment clinical trials 0.815475 bias 0.382394 Placebos 0.570523 standard treatment 0.968379 cancer 0.37398	CLICK HERE
16474	National Cancer Institute	Html	en	Daratumumab Improves Progression-Free Survival for Patients with Multiple Myeloma	A summary of clinical trial results showing that daratumumab plus lenalidomide and dexamethasone improved progression-free survival for patients with relapsed or refractory disease.	new therapies 0.572094 treatment discontinuation 0.574208 POLLUX study 0.57126 primary end point 0.630284 daratumumab group 0.876674 control group 0.792853 S. Vincent Rajkumar 0.618064 Dr. Little 0.676787 Cancer Therapy Evaluation 0.636324 POLLUX trials 0.571708 overall survival 0.568273 CASTOR trial 0.575567 Dr. Dimopoulos 0.584969 results 0.572512 median progression-free survival 0.728279 clinical trial 0.580723 individual patients 0.587776 POLLUX results 0.567653 multiple myeloma 0.997894 recent drug approvals 0.6372 patients 0.833916 refractory multiple myeloma 0.83253 subcutaneous bortezomib 0.587384 acute kidney injury 0.619235	breakthrough status 0.57273 treatment 0.577325 daratumumab group versus 0.686703 POLLUX trial 0.58049 Drug Administration 0.575079 disease progression 0.567898 common side effects 0.567783 prior therapy 0.637175 median follow-up 0.580658 phase III study 0.569672 European Hematology Association 0.647755 dexamethasone 0.669678 future randomized trials 0.618018 Richard Little 0.575379 prior treatments 0.57562 progression-free survival 0.753643 complete response 0.568115 ‘drug holidays 0.567081 Robert A. Kyle 0.617832 higher rate 0.614162 various triplet 0.567473 New England Journal 0.773927 CD38 protein 0.577198 monoclonal antibody 0.579931	CLICK HERE
17191	National Cancer Institute	Html	en	Sexual Health Issues in Men with Cancer	Cancer treatments such as chemotherapy, radiation therapy and prostate surgery may affect a man’s sexual function, lower libido, and make it difficult to get an erection. Learn how to manage and treat these sexual problems, during cancer treatment.	cancer treatment 0.61569 sex drive 0.572096 Health problems 0.586598 type 0.587796 treatment period 0.603714 surgical procedures 0.573864 health care team 0.738111 sexual life 0.64608 support group 0.639849 dry orgasm 0.578467 social worker 0.640478 blood flow 0.572279 sexual activity 0.730677 External-beam radiation therapy 0.638717 sexual health 0.783436 sexual drive 0.587105 blood vessels 0.644507 nerve-sparing surgery 0.577234 birth control 0.659416 Fertility Issues 0.65439 effects 0.575848 sexual problems 0.618576 radiation therapy 0.699689 long term 0.578855 valuable suggestions 0.571657	testosterone levels 0.661139 problems 0.712718 erection 0.590707 treatment 0.949932 chemotherapy drugs 0.574557 personal health factors 0.644395 cancer-related support services 0.632148 sexual health problem 0.648802 erectile dysfunction 0.577805 sexual function 0.590367 heart disease 0.576566 penile implant 0.575767 hormone therapy 0.647445 firm rod 0.571295 sexual changes 0.600696 sexual health expert 0.652134 support groups 0.572986 doctor 0.590327 pelvic cancers 0.575903 high blood pressure 0.63751 treatment options 0.598986 internal radiation therapy 0.638371 Prostate Cancer 0.579757 time 0.615092	CLICK HERE